Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis

被引:1
|
作者
Liu, Jing [1 ]
Chen, Wei [1 ]
Shao, Shihuan [1 ]
Chen, Yuanyuan [1 ]
Wang, Hongyi [1 ]
Xi, Yang [1 ]
Wang, Luyan [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Hypertens, 11 Xizhimen South St, Beijing 100044, Peoples R China
关键词
Angiotensin II AT1 receptor antagonists (ARBs); nocturnal blood pressure; hypertension; meta-analysis; MODERATE ESSENTIAL-HYPERTENSION; SERUM URIC-ACID; DOUBLE-BLIND; ANTIHYPERTENSIVE EFFICACY; CANDESARTAN CILEXETIL; OLMESARTAN MEDOXOMIL; KOREAN PATIENTS; OPEN-LABEL; 50; MG; LOSARTAN;
D O I
10.1080/07853890.2024.2362880
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundNocturnal blood pressure (BP) is correlated with an increased risk of cardiovascular events and is an important predictor of cardiovascular death in hypertensive patients.ObjectiveNocturnal BP control is of great importance for cardiovascular risk reduction. This systematic review and meta-analysis aimed to explore the efficacy of angiotensin receptor blockers (ARBs) for nocturnal BP reduction in patients with mild to moderate hypertension.MethodsPICOS design structure was used to formulate the data extraction. All statistical calculations and analyses were performed with R.ResultsSeventy-seven studies with 13,314 participants were included. The overall analysis indicated that nocturnal BP drop varied considerably among different ARBs. Allisartan (13.04 [95% CI (-18.41, -7.68)] mmHg), olmesartan (11.67 [95% CI (-14.12, -9.21)] mmHg), telmisartan (11.11 [95% CI (-12.12, -10.11)] mmHg) were associated with greater reduction in nocturnal systolic BP. In the aspect of the nocturnal-diurnal BP drop ratio, only allisartan was greater than 1. While, the variation tendency of last 4-6 h ambulatory BP was basically consistent with nocturnal BP. Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern.ConclusionsThis study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern. This meta-analysis explores the efficacy of Angiotensin II AT1 receptor antagonists (ARBs) on nocturnal blood pressure (BP) reduction in mild to moderate hypertension.The results demonstrate that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs.Allisartan can reduce nighttime BP more effectively than daytime BP, which also improve the dipping pattern.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme InhibitorsA Systematic Review and Meta-Analysis
    Daniel Caldeira
    Cláudio David
    Cristina Sampaio
    American Journal of Cardiovascular Drugs, 2012, 12 (4) : 263 - 277
  • [32] Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis
    Tandon, Puneeta
    Abraldes, Juan G.
    Berzigotti, Annalisa
    Carlos Garcia-Pagan, Juan
    Bosch, Jaime
    JOURNAL OF HEPATOLOGY, 2010, 53 (02) : 273 - 282
  • [33] RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS FOR THE REDUCTION OF PORTAL PRESSURE: A META-ANALYSIS AND SYSTEMATIC REVIEW
    Tandon, P.
    Abraldes, J. G.
    Berzigotti, A.
    Garcia-Pagan, J. C.
    Bosch, J.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S85 - S86
  • [34] Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis
    Raimondi, Sara
    Botteri, Edoardo
    Munzone, Elisabetta
    Cipolla, Carlo
    Rotmensz, Nicole
    DeCensi, Andrea
    Gandini, Sara
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 212 - 219
  • [35] Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Combination with Angiotensin-Receptor Blockers in Nondiabetic chronic Kidney Disease:A Systematic Review and Meta-Analysis
    Zhao, Mingming
    Ma, Sijia
    Yu, Yi
    Wang, Rumeng
    Chang, Meiying
    Zhang, Hanwen
    Qu, Hua
    Zhang, Yu
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (38) : 7961 - 7973
  • [36] Efficacy and Safety of Angiotensin Receptor Blockers in Older Patients: A Meta-Analysis of Randomized Trials
    Elgendy, Islam Y.
    Huo, Tianyao
    Chik, Veronica
    Pepine, Carl J.
    Bavry, Anthony A.
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (05) : 576 - 585
  • [37] Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension
    Heran, Balraj S.
    Wong, Michelle M. Y.
    Heran, Inderjit K.
    Wright, James M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [38] Efficacy of synbiotic interventions on blood pressure: a systematic review and meta-analysis of clinical trials
    Hadi, Amir
    Pourmasoumi, Makan
    Kazemi, Maryam
    Najafgholizadeh, Ameneh
    Marx, Wolfgang
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2022, 62 (20) : 5582 - 5591
  • [39] Stress reduction programs in patients with elevated blood pressure: A systematic review and meta-analysis
    Maxwell V. Rainforth
    Robert H. Schneider
    Sanford I. Nidich
    Carolyn Gaylord-King
    John W. Salerno
    James W. Anderson
    Current Hypertension Reports, 2007, 9
  • [40] Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis
    Kwok, Chun Shing
    Loke, Yoon K.
    Pradhan, Shiva
    Keavney, Bernard
    El-Omar, Magdi
    Mamas, Mamas A.
    OPEN HEART, 2014, 1 (01):